Connecta Therapeutics S.L. is a biotechnology company developing new treatments for unmet CNS medical needs.
The company is currently focused on the clinical development of a new first-in-class molecule, CTH120, for the treatment of fragile X syndrome (FXS). FXS is the most common cause of hereditary intellectual disability and there are currently no therapeutic interventions available.
CTH120 was designed after the study of more than 30 molecular and cellular targets for neuroplasticity. The molecule has been proven, in in vitro tests and in vivo in animal models, to be an excellent neuroplasticity modulator with a great extension profile for other neurodevelopmental disorders (Rett syndrome, Down syndrome and autism spectrum disorders, among others).